[
  {
    "table_index": 1,
    "headers": [],
    "rows": [
      [
        "End Note"
      ],
      [
        "Procite"
      ],
      [
        "Reference Manager"
      ]
    ],
    "row_count": 3,
    "column_count": 1
  },
  {
    "table_index": 2,
    "headers": [
      "",
      "Copper IUD",
      "Hormonal (Progestin) IUD",
      "CHCs (Pill, Patch, Ring)",
      "Progesterone‐Only Pills",
      "DMPA Injection",
      "Subcutaneous Implant"
    ],
    "rows": [
      [
        "Strengths",
        "Failure rate <1%, convenient, does not rely on adherence, no estrogen‐associated risks, effective at least 10 years",
        "Failure rate <1%, convenient, does not rely on adherence, no estrogen‐associated risks, lightens menses, effective at least 3‐5 years",
        "Regular bleeding, lightened menses",
        "No estrogen‐associated risks",
        "No estrogen‐associated risks, injections every 3 months",
        "Failure rate <1%, convenient, does not rely on adherence, no estrogen‐associated risks, effective at least 3 years"
      ],
      [
        "Limitations or concerns",
        "Increased menstrual cramping and bleeding (less ideal if anemia or low platelets)",
        "Irregular bleeding common",
        "Typical failure rate 9%, contraindications as denoted subsequently, interacts with P450, associated with hypertension, VTE, and (less commonly) stroke and rare cholestatic liver injury",
        "Typical failure rate 9%, requires strict daily timing, possible conversion of high‐dose progestins to small amount of estrogen (unlikely relevant with modern‐day, lower‐dose progestin preparations), irregular bleeding common",
        "Typical failure rate 6%, irregular bleeding common, can decrease bone density (less favored for liver diseases associated with osteopenia/osteoporosis)",
        "Irregular bleeding common"
      ],
      [
        "CDC MEC safety categories/AASLD recommendations"
      ],
      [
        "Cirrhosis",
        "",
        "",
        "",
        "",
        "",
        ""
      ],
      [
        "Compensated",
        "1/Acceptable",
        "1/Acceptable",
        "1/Acceptable",
        "1/Acceptable",
        "1/Acceptable, but less favored",
        "1/Acceptable"
      ],
      [
        "Decompensated",
        "1/Acceptable",
        "3/Acceptable",
        "4/Unacceptable",
        "3/Acceptable",
        "3/Acceptable, but less favored",
        "3/Acceptable"
      ],
      [
        "BCS",
        "2/Acceptable",
        "2/Acceptable",
        "4/Unacceptable",
        "2/Acceptable",
        "2/Acceptable",
        "2/Acceptable"
      ],
      [
        "HCAs",
        "1/Acceptable",
        "3/Acceptable",
        "4/Unacceptable",
        "3/Acceptable",
        "3/Acceptable",
        "3/Acceptable"
      ],
      [
        "Posttransplant graft function",
        "",
        "",
        "",
        "",
        "",
        ""
      ],
      [
        "Normal",
        "2/Acceptable",
        "2/Acceptable",
        "2/Acceptable",
        "2/Acceptable",
        "2/Acceptable, but less favored",
        "2/Acceptable"
      ],
      [
        "Graft failure",
        "3/Acceptable",
        "3/Acceptable",
        "4/Unacceptable",
        "2/Acceptable",
        "2/Acceptable, but less favored",
        "2/Acceptable"
      ]
    ],
    "row_count": 11,
    "column_count": 7
  },
  {
    "table_index": 3,
    "headers": [
      "Modality",
      "Fetal Dose (mGy)",
      "Maternal Dose (mSv)"
    ],
    "rows": [
      [
        "CT abdomen/pelvis (no contrast)",
        "13‐25",
        "3‐45"
      ],
      [
        "Chest, two views",
        "0.0005‐0.01",
        "0.06‐0.29"
      ],
      [
        "Abdominal radiography",
        "0.1‐0.3",
        "0.01‐1.1"
      ],
      [
        "Double‐contrast barium enema",
        "1.0‐20",
        "2.0‐18.0"
      ],
      [
        "Small‐bowel examination",
        "7",
        "3.0‐7.8"
      ],
      [
        "Endoscopic retrograde cholangiopancreatiography*",
        "0.1‐0.3",
        "2‐6"
      ]
    ],
    "row_count": 6,
    "column_count": 3
  },
  {
    "table_index": 4,
    "headers": [
      "Medication",
      "Pregnancy",
      "Lactation",
      "Fertility",
      "Historical FDA Classification"
    ],
    "rows": [
      [
        "Acamprosate",
        "Animal data suggest risk of fetal abnormalities; human data are limited; decision about use involves careful consideration of risks of continued alcohol use versus medication exposure",
        "Limited human data",
        "No human data",
        "C"
      ],
      [
        "Careful consideration of risks of continued maternal alcohol use vs. medication exposure"
      ],
      [
        "Acyclovir",
        "Compatible",
        "Compatible",
        "Animal data demonstrated testicular atrophy and aspermatogenesis; human data do not demonstrate this",
        "B"
      ],
      [
        "Antihistamines (chlorpheniramine, diphenhydramine, hydroxyzine)",
        "Compatible",
        "Compatible in low doses",
        "No human data",
        "Chlorpheniramine: B"
      ],
      [
        "High doses may be associated with sedation in infants or decreases in breast milk supply",
        "Diphenhydramine: B"
      ],
      [
        "Hydroxyzine is less preferred due to limited data reporting adverse reactions (mostly sedation) in infants",
        "Hydroxyzine: C"
      ],
      [
        "Beta‐blockers (carvedilol, nadolol, propranolol)",
        "Carvedilol: no data",
        "Carvedilol: no data",
        "Carvedilol: Animal studies suggest protection from diabetes mellitus–induced testicular damage; no human data",
        "Carvedilol: C"
      ],
      [
        "Nadolol, propranolol: overall compatible despite reports of intrauterine growth restriction, neonatal respiratory depression, and infant hypoglycemia",
        "Nadolol: less preferred due to extensive level of excretion into breast milk and its renal excretion",
        "Nadolol: no adverse effects on fertility in animals; no human data",
        "Nadolol: C"
      ],
      [
        "Propranolol is preferred; shorter half‐life and less protein‐bound than nadolol",
        "Propranolol: compatible; highly protein bound and excreted in milk in small amounts",
        "Propranolol: associated with impotence in men; no data in women",
        "Propranolol: C"
      ],
      [
        "Cephalosporins (cefotaxime, ceftriaxone)",
        "Compatible",
        "Compatible",
        "Cefotaxime: animal data showed no adverse effect on fertility; no human data available",
        "B"
      ],
      [
        "Ceftriaxone: animal data are mixed, showing decreased sperm concentration and motility in some studies and no effect on fertility in other studies; no human data available"
      ],
      [
        "Cholestyramine",
        "Compatible",
        "Compatible",
        "No human data",
        "C"
      ],
      [
        "High doses can lead to vitamin K deficiency and increased risk of fetal hemorrhage"
      ],
      [
        "d‐penicillamine",
        "Teratogenicity has been documented, but discontinuation in pregnancy may also have deleterious maternal effects",
        "Limited data suggest that it is not detectable in human breast milk and that it is compatible with breastfeeding",
        "No data",
        "D"
      ],
      [
        "May continue with dose adjustments made across pregnancy",
        "Copper and zinc levels are reduced in the breast milk of women takingd‐penicillamine"
      ],
      [
        "DAA agents for HCV (glecaprevir/pibrentasvir, ledipasvir/sofosbuvir, sofosbuvir/velpatasvir)",
        "Glecaprevir/pibrentasvir, ledipasvir/sofosbuvir: no birth defects reported in animal data",
        "Detected in rat milk",
        "No effect on fertility in rats",
        "Glecaprevir/pibrentasvir, sofosbuvi/velpatasvir: none assigned"
      ],
      [
        "Increase in visceral malformations with exposure of velpatasvir alone in rabbits",
        "No human data",
        "No human data",
        "Ledipasvir/sofosbuvir: B"
      ],
      [
        "Disulfiram",
        "Associated with fetal malformations",
        "Avoid",
        "No data",
        "None assigned"
      ],
      [
        "Decision about use involves careful consideration of risks of continued alcohol use versus medication exposure"
      ],
      [
        "Entecavir",
        "Avoid due to insufficient data",
        "Avoid due to insufficient data",
        "No human data",
        "C"
      ],
      [
        "Fluoroquinolones (ciprofloxacin, norfloxacin, ofloxacin)",
        "Avoid due to toxic effects on developing cartilage in animal studies and reports of arthralgias and tendonitis in adolescents",
        "Compatible with monitoring for infant GI infections (Clostridioides difficile, Candida) that have been reported with use in lactating women",
        "Animal data are mixed, showing sperm DNA impairment and impaired sperm motility in some studies and no effect on fertility in other animal studies; limited human data available",
        "C"
      ],
      [
        "Heparin (low‐molecular‐weight heparin)",
        "Compatible",
        "Compatible",
        "Animal studies indicated no effect on fertility; no human data",
        "B"
      ],
      [
        "Lamivudine",
        "Compatible",
        "Compatible",
        "No adverse effect on fertility in animal studies; no human data",
        "C"
      ],
      [
        "Naltrexone",
        "Compatible",
        "Compatible",
        "Limited data suggest possible restoration of ovulation in patients with ovulation disorders",
        "C"
      ],
      [
        "Obeticholic acid",
        "Avoid due to lack of data.",
        "Avoid due to lack of data.",
        "No data",
        "None assigned"
      ],
      [
        "Octreotide",
        "Careful consideration for use; advise use in setting of acute variceal bleed, as benefits outweigh risks",
        "Limited human data suggest compatibility",
        "No increased adverse effects on fertility in females; no human data in men",
        "B"
      ],
      [
        "Limited human data (reports of fetal growth restriction but no congenital malformations)",
        "Poor excretion into breast milk due to its high molecular weight"
      ],
      [
        "Pegylated interferon alpha",
        "Human data report successful use of interferon alpha; animal data report abortifacient potential",
        "Unlikely to pose risk due to low levels in milk and poor absorption by infant",
        "Animal data suggest association with impaired fertility",
        "C"
      ],
      [
        "Use if potential benefit outweighs potential risk"
      ],
      [
        "Ribavirin",
        "Avoid due to teratogenicity and embryocidal effects observed in multiple animal studies",
        "No data in lactating mothers treated for hepatitis C infection",
        "Avoid use in women and men for 6 months before conception",
        "X"
      ],
      [
        "Rifampin",
        "Compatible",
        "Compatible",
        "May decrease effectiveness of some oral contraceptives due to hepatic enzyme induction",
        "C"
      ],
      [
        "Due to induction of P450 hepatic enzymes, it may be associated with vitamin degradation and subsequent hemorrhage in neonates (prophylactic vitamin K has been recommended)",
        "Detectable in breast milk at low levels",
        "No other fertility data available"
      ],
      [
        "S‐adenosylmethionine",
        "Compatible",
        "No data",
        "Insufficient data",
        "None assigned"
      ],
      [
        "Single study reported increase in sperm motility"
      ],
      [
        "Tenofovir (tenofovir disoproxil fumarate; TAF)",
        "Tenofovir disoproxil fumarate: compatibleTAF: no human data",
        "Tenofovir disoproxil fumarate: no contraindication for use",
        "Tenofovir disoproxil fumarate: limited human data suggest no adverse effect on fertility in men",
        "Tenofovir disoproxil fumarate: C"
      ],
      [
        "TAF: no human data",
        "TAF: no data",
        "TAF: none assigned"
      ],
      [
        "Terlipressin",
        "Avoid: data demonstrate that it can cause uterine contractions and decreased uterine blood flow",
        "No data: unknown if terlipressin is excreted into breast milk",
        "No data",
        "Currently not FDA approved"
      ],
      [
        "Trientine",
        "Compatible with dose adjustments made across pregnancy",
        "Limited data suggest that it is not detectable in human milk and compatible with breastfeeding",
        "No data",
        "C"
      ],
      [
        "Conflicting data on whether copper and zinc levels are reduced in the breast milk of women taking trientine"
      ],
      [
        "UDCA",
        "Compatible",
        "Compatible",
        "Limited animal data suggest no adverse effects on fertility",
        "B"
      ],
      [
        "Zinc",
        "Compatible",
        "Maternal zinc supplementation does not alter zinc concentrations in breast milk",
        "No adverse effect on fertility in men",
        "C"
      ]
    ],
    "row_count": 41,
    "column_count": 5
  },
  {
    "table_index": 5,
    "headers": [
      "Medication",
      "Pregnancy",
      "Lactation",
      "Fertility",
      "Historical FDA Classification"
    ],
    "rows": [
      [
        "6‐MP, Azathioprine",
        "Compatible",
        "Compatible",
        "6‐MP: normal ovarian function; mixed data in men, with reports of birth defects in children fathered by men taking 6‐MP and other data showing no increased rates of birth defects",
        "D"
      ],
      [
        "6‐MP: no increased risk of birth defects",
        "Some reports of self‐limited neutropenia"
      ],
      [
        "Azathioprine: associated with low birth weight and preterm birth"
      ],
      [
        "Azathioprine: no increased likelihood of adverse effects on fertility in females and males"
      ],
      [
        "CNIs (cyclosporine, tacrolimus)",
        "Compatible",
        "Compatible",
        "No known risk to fertility in females and males",
        "C"
      ],
      [
        "Cyclosporine: reports of association with low birth weight"
      ],
      [
        "Tacrolimus: reports of association with hypertension, preeclampsia, and preterm birth"
      ],
      [
        "Glucocorticoids (budesonide, prednisone)",
        "Compatible",
        "Compatible",
        "Budesonide: no effect on fertility in rats; no human data",
        "C"
      ],
      [
        "Prednisone: possible association with oral clefting",
        "Prednisone: no increased likelihood of adverse pregnancy outcomes when used in males of reproductive potential"
      ],
      [
        "Budesonide: may lower fetal exposure"
      ],
      [
        "mTOR inhibitors (sirolimus, everolimus)",
        "Not recommended due to limited human data",
        "Not recommended due to limited human data",
        "Sirolimus: reports of irregular ovulation and ovarian cysts; reports of decreased sperm counts and decreased male fertility",
        "Sirolimus: C"
      ],
      [
        "Everolimus: rare reports of reduced sperm count and decreased male fertility",
        "Everolimus: not assigned"
      ],
      [
        "MPA products (mycophenolate mofetil, mycophenolate sodium)",
        "Contraindicated",
        "No reported adverse events",
        "No known risk to fertility in females and males",
        "D"
      ],
      [
        "High risk of miscarriage and birth defects",
        "Use not advised, given the adverse outcomes observed in pregnancy",
        "In women, discontinue use at least 6 weeks before conception"
      ]
    ],
    "row_count": 14,
    "column_count": 5
  },
  {
    "table_index": 6,
    "headers": [
      "Baseline Pregnancy Weight Category",
      "BMI Prepregnancy",
      "Weight Gain During Pregnancy (lb)",
      "Rate of Weight Gain During Second and Third Trimesters"
    ],
    "rows": [
      [
        "Underweight",
        "<18.5",
        "28‐40",
        "1‐1.13"
      ],
      [
        "Normal",
        "18.5‐24.9",
        "25‐35",
        "0.8‐1"
      ],
      [
        "Overweight",
        "25‐28.9",
        "15‐25",
        "0.5‐0.7"
      ],
      [
        "Obese",
        "≥30",
        "11‐20",
        "0.4‐0.6"
      ]
    ],
    "row_count": 4,
    "column_count": 4
  },
  {
    "table_index": 7,
    "headers": [
      "",
      "Hyperemesis Gravidarum",
      "ICP",
      "HELLP",
      "AFLP"
    ],
    "rows": [
      [
        "Trimester",
        "First (rare second/third)",
        "Second or third",
        "Second or third",
        "Third or postpartum"
      ],
      [
        "Prevalence",
        "0.35%‐2.0%",
        "0.4%‐10%",
        "0.2%‐0.6% (preeclampsia affects 3%‐5%)",
        "0.005%‐0.010%"
      ],
      [
        "Risk factors",
        "Prior history",
        "Multiparous, metabolic syndrome, HCV infection, personal or family history of ICP, ABCB11, ABCB4, and ATP8B1 mutations",
        "Preexisting hypertension, DM, advanced maternal age, multiple gestations, previous history of preeclampsia",
        "Primiparous, multiple gestations, male fetus"
      ],
      [
        "Clinical findings",
        "Vomiting with weight loss ≥5% of prepregnancy body weight, dehydration",
        "Generalized pruritus, especially palms and soles, without rash",
        "Abdominal pain, nausea/vomiting; commonly have preeclampsia",
        "Abdominal pain, nausea/vomiting, jaundice, hypoglycemia"
      ],
      [
        "If hepatic failure, will have encephalopathy"
      ],
      [
        "Laboratory findings",
        "Abnormal AST and ALT seen in ~ 50% but rarely >1,000 U/L and typically improve with hydration",
        "AST and ALT 2‐30 times the ULN",
        "AST and ALT typically >500 units/L",
        "AST and ALT 300‐1,000 U/L"
      ],
      [
        "Jaundice rare",
        "Total bile acids >10 μmol/L",
        "Platelets <50 L to 150 × 109/L Bilirubin <5 mg/dL",
        "Low antithrombin III, elevated PT, low fibrinogen, elevated bilirubin, elevated LDH"
      ],
      [
        "Ketonuria",
        "Hemolysis (schistocytes, spherocytes, reticulocytes); hyperuricemia, markedly elevated LDH >600 units/L",
        "Platelets <100,000 × 109/L"
      ],
      [
        "Electrolyte abnormalities",
        "If ALF, will have coagulopathy, hypoglycemia, hyperuricemia, and DIC"
      ],
      [
        "Diagnosis",
        "Clinical",
        "Clinical plus elevated bile acids >10 μmol/L are sufficient for diagnosis",
        "Clinical + maternal organ dysfunction, including renal, hepatic, neurologic, or hematologic complications, uteroplacental dysfunction, or fetal growth restriction",
        "Clinical"
      ],
      [
        "Upper endoscopy rarely indicated",
        "Elevated AST and ALT are frequent but not necessary for diagnosis",
        "Swansea criteria can be used (high sensitivity but low specificity if acute liver failure)"
      ],
      [
        "US may exclude biliary causes if needed"
      ]
    ],
    "row_count": 12,
    "column_count": 5
  }
]